Canada
· Delayed Price · Currency is CAD MediPharm Labs Statistics
Total Valuation
MediPharm Labs has a market cap or net worth of CAD 37.36 million. The enterprise value is 29.04 million.
| Market Cap | 37.36M |
| Enterprise Value | 29.04M |
Important Dates
The last earnings date was Thursday, May 15, 2025.
| Earnings Date | May 15, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
MediPharm Labs has 415.14 million shares outstanding. The number of shares has increased by 4.01% in one year.
| Current Share Class | 415.14M |
| Shares Outstanding | 415.14M |
| Shares Change (YoY) | +4.01% |
| Shares Change (QoQ) | +0.80% |
| Owned by Insiders (%) | 6.71% |
| Owned by Institutions (%) | 0.00% |
| Float | 387.28M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.87 |
| PB Ratio | 0.86 |
| P/TBV Ratio | 0.88 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -3.89 |
| EV / Sales | 0.68 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -4.45 |
Financial Position
The company has a current ratio of 3.61, with a Debt / Equity ratio of 0.00.
| Current Ratio | 3.61 |
| Quick Ratio | 1.84 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.02 |
| Interest Coverage | -11.37 |
Financial Efficiency
Return on equity (ROE) is -16.05% and return on invested capital (ROIC) is -7.18%.
| Return on Equity (ROE) | -16.05% |
| Return on Assets (ROA) | -6.04% |
| Return on Invested Capital (ROIC) | -7.18% |
| Return on Capital Employed (ROCE) | -12.66% |
| Revenue Per Employee | 267,056 |
| Profits Per Employee | -46,398 |
| Employee Count | 161 |
| Asset Turnover | 0.76 |
| Inventory Turnover | 2.78 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +12.50% in the last 52 weeks. The beta is 0.32, so MediPharm Labs's price volatility has been lower than the market average.
| Beta (5Y) | 0.32 |
| 52-Week Price Change | +12.50% |
| 50-Day Moving Average | 0.09 |
| 200-Day Moving Average | 0.07 |
| Relative Strength Index (RSI) | 50.24 |
| Average Volume (20 Days) | 178,720 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, MediPharm Labs had revenue of CAD 43.00 million and -7.47 million in losses. Loss per share was -0.02.
| Revenue | 43.00M |
| Gross Profit | 15.07M |
| Operating Income | -5.48M |
| Pretax Income | -7.47M |
| Net Income | -7.47M |
| EBITDA | -3.31M |
| EBIT | -5.48M |
| Loss Per Share | -0.02 |
Balance Sheet
The company has 8.44 million in cash and 125,000 in debt, giving a net cash position of 8.32 million or 0.02 per share.
| Cash & Cash Equivalents | 8.44M |
| Total Debt | 125,000 |
| Net Cash | 8.32M |
| Net Cash Per Share | 0.02 |
| Equity (Book Value) | 43.23M |
| Book Value Per Share | 0.10 |
| Working Capital | 23.00M |
Cash Flow
In the last 12 months, operating cash flow was -6.35 million and capital expenditures -175,000, giving a free cash flow of -6.52 million.
| Operating Cash Flow | -6.35M |
| Capital Expenditures | -175,000 |
| Free Cash Flow | -6.52M |
| FCF Per Share | -0.02 |
Margins
Gross margin is 35.05%, with operating and profit margins of -12.74% and -17.37%.
| Gross Margin | 35.05% |
| Operating Margin | -12.74% |
| Pretax Margin | -17.37% |
| Profit Margin | -17.37% |
| EBITDA Margin | -7.70% |
| EBIT Margin | -12.74% |
| FCF Margin | n/a |
Dividends & Yields
MediPharm Labs does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4.01% |
| Shareholder Yield | -4.01% |
| Earnings Yield | -19.99% |
| FCF Yield | -17.46% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |